Arcadia Biosciences (RKDA) AI Stock Analysis

• Market Cap: $3.10M
• Dividend Yield: N/A
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.82
• Revenue Growth: -1.80%
• EPS Growth: 15.74%
• Country: US
• Employees: 9
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Agricultural Inputs
• EPS (TTM): -0.85
• Shares Outstanding: 1,373,120
• 10 Day Avg. Volume: 3,254,407
• 30 Day Avg. Volume: 1,090,692
• PEG Ratio: 0.02
• Price to Book (P/B): 1.30
• Price to Sales (P/S): 1.60
• P/FCF Ratio: -0.84
• Enterprise Value/Market Cap: 0.47
• Enterprise Value/Revenue: 0.28
• Enterprise Value/Gross Profit: 0.74
• Enterprise Value/Ebitda: -0.36
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $2.00 ▼(-37.69% Downside)

The score is held down primarily by weak financial performance—ongoing large losses and persistent cash burn—while technicals also point to a bearish trend with the stock below key moving averages. A debt-free balance sheet and mixed corporate updates provide only limited offset, and valuation metrics are not supportive given the company’s unprofitability and lack of dividend data.

Positive Factors

Proprietary Crop Technology

Arcadia’s core expertise in plant breeding and genetic engineering supports seed sales, licensing, and partnerships. Proprietary tech creates product differentiation and recurring royalty/licensing potential, providing a durable competitive advantage that can drive medium-term revenue expansion if commercialized effectively.

Debt-Free Balance Sheet

A debt-free trailing twelve months position reduces fixed financial obligations and interest burden, giving management structural financial flexibility. This strengthens the company’s runway for R&D, strategic transactions, or operational scaling without immediate debt servicing risk, improving long-term optionality.

Strategic Assets & Governance

The company’s holdings (Above Food shares, Zola brand) plus a Nasdaq listing and recent director re-elections provide tangible assets and governance continuity. These structural factors expand realistic strategic alternatives—spin-offs, asset sales, or mergers—that can unlock value over a multi-month timeframe.

Negative Factors

Persistent Cash Burn

Sustained negative operating and free cash flow (~-$6.1M TTM) creates ongoing liquidity pressure and heightens the need for external financing or asset monetization. Over a multi-month horizon this increases dilution risk, limits reinvestment in commercialization, and constrains the company’s ability to execute long-term plans.

Small, Declining Revenue Base

A modest and falling revenue base (~$5.2M TTM) indicates limited commercial traction and weak scaling dynamics. Without durable top-line growth, fixed costs and R&D spend cannot be absorbed, delaying path to sustainable profitability and making long-term margin expansion difficult without new, repeatable revenue streams.

Deep Unprofitability

Very large operating and net losses reflect structural lack of operating leverage and negative returns on capital. Persistent deep unprofitability erodes equity and investor value, indicating that without meaningful improvement in margins or revenue mix the company faces a prolonged uphill battle to generate positive, sustainable cash flows.

Arcadia Biosciences Business Overview & Revenue Model

Company Description

Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.

How the Company Makes Money

Arcadia Biosciences generates revenue primarily through the commercialization of its proprietary crop varieties and technology licenses. The company earns money by selling seeds of its high-value crops, which are designed for better nutritional profiles and improved performance in various environmental conditions. Additionally, revenue is supplemented through collaborations and partnerships with other agricultural companies and research institutions, where they license their technology for use in developing new crop varieties. These partnerships often include upfront payments and milestone payments as products are developed, along with royalties on future sales. Strategic alliances with agricultural producers and distributors further enhance their market reach and revenue potential.

Arcadia Biosciences Financial Statement Overview

Summary

Arcadia Biosciences is facing financial challenges, particularly with profitability and cash flow generation. Revenue has declined, and the company remains unprofitable, although it has managed to maintain a strong equity position with minimal debt. The company needs to address its operational efficiency and cash flow management to improve its financial stability.

Income Statement

Arcadia Biosciences has faced challenges in maintaining revenue growth and profitability. The revenue decreased slightly from $5.33 million in 2023 to $5.045 million in 2024, indicating a revenue decline of approximately 5.35%. The gross profit margin improved slightly, but the company remains unprofitable with a negative net income for the year ending 2024. EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The balance sheet shows a moderate level of financial stability with a debt-to-equity ratio of 0.025, indicating low leverage. However, the return on equity remains negative due to consistent net losses. The equity ratio is 46%, indicating a solid equity position relative to total assets.

Cash Flow

Arcadia Biosciences experienced substantial free cash flow challenges, with negative free cash flow growth. Operating cash flow to net income ratio is negative, reflecting cash flow difficulties. However, cash flow from investing activities was positive, indicating some level of investment recovery.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.17M	5.04M	4.45M	7.42M	6.78M	8.03M
Gross Profit	1.96M	2.08M	2.28M	1.32M	-1.93M	2.83M
EBITDA	-4.09M	-7.50M	-5.73M	-14.75M	-27.71M	-5.44M
Net Income	-5.07M	-7.04M	-13.98M	-15.38M	-14.66M	-4.66M
Balance Sheet
Total Assets	8.58M	13.52M	19.70M	28.92M	43.92M	47.35M
Cash, Cash Equivalents and Short-Term Investments	5.88M	4.24M	11.64M	20.64M	28.68M	25.67M
Total Debt	0.00	155.00K	1.01M	2.02M	3.29M	9.35M
Total Liabilities	3.14M	7.29M	7.00M	8.02M	12.72M	18.80M
Stockholders Equity	5.44M	6.22M	12.84M	21.03M	31.09M	27.73M
Cash Flow
Free Cash Flow	-6.09M	-9.64M	-15.30M	-14.05M	-26.88M	-32.55M
Operating Cash Flow	-6.09M	-9.63M	-15.29M	-13.98M	-25.87M	-30.22M
Investing Cash Flow	3.27M	7.34M	-4.34M	1.42M	16.61M	17.28M
Financing Cash Flow	6.00K	9.00K	5.51M	4.52M	21.90M	20.56M

Arcadia Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RKDA, the sentiment is Negative. The current price of 3.21 is above the 20-day moving average (MA) of 2.68, below the 50-day MA of 3.28, and below the 200-day MA of 3.83, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 40.49 is Neutral, neither overbought nor oversold. The STOCH value of 53.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RKDA.

Arcadia Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
BIOX	49 Neutral	$77.77M	-1.44	-20.52%	―	-27.90%	-4194.67%
SEED	46 Neutral	$14.45M	-19.88	―	―	-21.82%	-104.92%
RKDA	45 Neutral	$3.10M	-0.65	-64.08%	―	-1.80%	15.74%
AVD	45 Neutral	$114.73M	-1.10	-40.84%	―	-4.29%	-276.74%
BHST	45 Neutral	$117.24M	-7.44	-200.22%	―	45.88%	43.12%
LVRO	45 Neutral	$120.33M	-0.32	―	―	―	―

Arcadia Biosciences Corporate Events

Arcadia Biosciences Executes Inducement Financing to Bolster Liquidity

On January 9, 2026, Arcadia Biosciences entered into inducement agreements with certain investors to immediately exercise previously issued preferred investment options for 808,595 shares of common stock, cutting the exercise price from $9.00 to $2.575 per share. The transaction, which closed on January 12, 2026, generated approximately $2.1 million in gross proceeds earmarked for working capital and general corporate purposes, and in exchange the company issued new unregistered preferred investment options for up to 1,617,190 shares at an exercise price of $2.325, along with additional placement agent options and related fee payments to H.C. Wainwright & Co. The deal modestly strengthens Arcadia’s near-term liquidity while introducing further potential dilution, and includes restrictions on new equity issuance and variable-rate financings for defined periods, shaping the company’s capital-raising flexibility going forward.

The most recent analyst rating on (RKDA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Arcadia Biosciences stock, see the RKDA Stock Forecast page.

Arcadia Biosciences Executes Inducement Financing to Bolster Liquidity

On January 9, 2026, Arcadia Biosciences entered into inducement agreements with certain investors to immediately exercise previously issued preferred investment options for 808,595 shares of common stock, cutting the exercise price from $9.00 to $2.575 per share. The transaction, which closed on January 12, 2026, generated approximately $2.1 million in gross proceeds earmarked for working capital and general corporate purposes, and in exchange the company issued new unregistered preferred investment options for up to 1,617,190 shares at an exercise price of $2.325, along with additional placement agent options and related fee payments to H.C. Wainwright & Co. The deal modestly strengthens Arcadia’s near-term liquidity while introducing further potential dilution, and includes restrictions on new equity issuance and variable-rate financings for defined periods, shaping the company’s capital-raising flexibility going forward.

The most recent analyst rating on (RKDA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Arcadia Biosciences stock, see the RKDA Stock Forecast page.

Arcadia Biosciences strategic review after merger termination

On December 24, 2025, Arcadia Biosciences received a notice from Roosevelt Resources, LP terminating their all-stock Securities Exchange Agreement, originally signed on December 4, 2024 and amended on April 30, 2025, after the planned business combination failed to close by the extended August 15, 2025 termination date. Arcadia said it does not expect any break-up fee to be payable by either party and will now resume evaluating strategic alternatives to create shareholder value, highlighting its streamlined operations, reduced expenses, ownership of approximately 2.7 million shares of Above Food Ingredients Inc., potential additional consideration tied to its May 2024 sale of the GoodWheat business, its Nasdaq listing and its Zola coconut water brand as assets that could support a future merger or other strategic transaction.

The most recent analyst rating on (RKDA) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Arcadia Biosciences stock, see the RKDA Stock Forecast page.

Arcadia Biosciences Stockholders Back Directors and Governance Moves

At its annual meeting of stockholders held on December 19, 2025, Arcadia Biosciences reported that holders of approximately 51% of its outstanding common shares were present in person or by proxy, providing the quorum needed to conduct business. Stockholders elected three Class I directors, Albert Bolles, Kevin Comcowich and Thomas J. Schaefer, to serve until the 2028 annual meeting, approved on an advisory basis the compensation of the company’s named executive officers, and ratified the appointment of Deloitte & Touche LLP as Arcadia’s independent registered public accountants for the fiscal year ending December 31, 2025, signaling continued shareholder support for the company’s leadership, governance structure and financial oversight.

The most recent analyst rating on (RKDA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Arcadia Biosciences stock, see the RKDA Stock Forecast page.

Arcadia Biosciences Announces 2025 Annual Meeting Date

Arcadia Biosciences, Inc. has announced that its 2025 annual meeting of stockholders will be held on December 19, 2025. The company has also informed stockholders of a change in the meeting date and updated deadlines for submitting proposals and nominations for the meeting. This announcement follows a Securities Exchange Agreement with Roosevelt Resources, LP, which involves an all-stock transaction for the combination of the two companies. The meeting and the proxy statement are separate from the special meeting related to this transaction.

The most recent analyst rating on (RKDA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Arcadia Biosciences stock, see the RKDA Stock Forecast page.